Working till I drop over dead thanks AAPL

AAPL missed earnings est. but just a little. I'll sell the three calls one at a time, one in Dec, Jan and Feb, hoping I can cut the loss to 40% which is still a big loss. AAPL closed down $5.54 at $604 alot of volume 36.7 million shares. The three month avg. volume is 16.7 million shares. ................................................... .............................................................................................................................................................................. Geron up 3 cents at $1.30 volume a little better at 1.2 million shares. Dec, Geron will tell us how the last 4 Phase two trials are going. If there is any run up I'm sell 5 thousand shares. Geron as been batting zero I can't lose more money on this company. .............................................................................................................................................................................. ACTC down a little at 0.0701 on 4.4 million shares. Need news or we go lower........... .............................................................................................................................................................................. Good luck in this rigged casino,

AAPPL, ACTC and Geron all up

AAPL was up $3.47 to close at $616.83 on 19.8 million shares. Thursday is the make or break day for my calls. Need blow out earnings and a $50+ run up....................... .....................................................................................................................................................................................................................................................................ACTC up a little at 0.0710. Only 3.9 million shares the three month avg. volume is 5.7 million shares. With no news we go lower. May buy a little under 7 cents............... ............................................................................................................................................................................................................................................................................................................................................................ Geron no news on the deal, I'm betting Chip will tell all Oct 30th at 4:30PM it will be webcast, earninngs call. Geron closed at $1.34 up 2 cents volume was only 405,164 shares. There's no interest in this company. Need good news on the last 4 Phase two trials. If no good news we go under $1.....................................................................................May add BTX to my holdings but only 100 shares................................... .......................................................................................Good luck in this rigged casino,

AAPL down big, ACTC and Geron down

AAPL's iPod mini looks great but the $329 price may be to much, so the market thinks. I'm thinking they will sell 10 million+. Down $20.67 to close at $613.36, volume was 25.1 million shares. The three month avg. volume 16.3 million shares. ..................................................................................................................................................................................................................................................................................ACTC down a little at 0.0702, holding 7 cents but not for long without good news. ..................................................................................................................................................................................................................................................................................Geron down a little at $1.32 on 768,621 shares. No word on the BioTime deal..................................................................................................................................................................................................................................................................Good luck in this rigged casino,

Tom Okarma working for BTX was working for Geron

Dr West is CEO of BioTime and was the founder of Geron. Tom Okarma was hired by Dr. West who also worked at Geron and was a leader in the embryonic movement. Was Geron sell [more like give it to BioTime] it to Dr. West. Maybe. If I remember what I read GE has the right to review any deal and make a deal with Geron. Geron closed down 0.055 cents at $1.38. The volume was low only 452,103 shares ..................................................................................................................................... ..................................................................................................................................................................................................................................................................... ACTC closed down a little at 0.0715. I think we go under 6 maybe by Dec................ ..............................................................................................................................................................................AAPL up big to close at $634.03, need $40 more for my calls. The iPod mini Tue. and earnings Thur.......................................................................... ..............................................................................................................................................................................Good luck in this rigged casino,

ACTC Clinical Trial Advances

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its European clinical trial for Stargardt’s Macular Dystrophy (SMD). The patient was injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial (RPE) cells, as compared with 50,000 cells in the three patients comprising the first cohort. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully. “Our progress continues in our European clinical trial and both our trials in the U.S., as seen most recently with last week’s announcement of treatment of the second patient in the second patient cohort of our U.S. trial for SMD,” said Gary Rabin, chairman and CEO of ACT. “As I mentioned last week, we have mapped out the series of patients to complete the second cohort of both our trials for SMD, as well as for our trial for dry age-related macular degeneration (dry AMD), pending DSMB review, and we anticipate generating patient data at a faster pace.” Initiated in January of this year, the Phase I/II trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study’s primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. The company is concurrently conducting another trial for SMD and one for dry AMD, both in the U.S. “We are very gratified to be initiating the first treatment of the second patient cohort in our European clinical trial, having just started it this year,” commented Robert Lanza, M.D., ACT’s chief scientific officer. “Our two U.S. trials also continue to move steadily forward.” Further information about patient eligibility for ACT’s SMD study and the concurrent studies in the U.S. and Europe (for dry age-related macular degeneration and SMD, respectively) are available at www.clinicaltrials.gov, with the following Identifiers: NCT01469832 (E.U. SMD), NCT01345006 (U.S. SMD), and NCT01344993 (dry AMD). About Stargardt’s Disease Stargardt’s disease or Stargardt’s Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium, which is the site of damage that the company believes the hESC-derived RPE may be able to target for repair after administration........................................................ ..................................................................................................................................................................................................................................................................... Good news, I hope the results are great. This would be great news for all the stem cell companies and the science....................................................... ..................................................................................... Good luck in this rigged casino,

It's a Small World for Geron

I was reading about BioTime and found Dr. Michael West is CEO of BioTime. Dr. West was also the founder of Geron 20+ years ago. He left Geron a few years back. Now Dr. West wants to buy his baby back, nice. Also BioTime uses ACTCellerate technology, yea ACTC what a small world. I'm thinking there's a game being played here and the shareholders are not in on it...................................................................... .............................................................................................................................................................................. Good luck in this rigged casino,

Geron, ACTC, AAPL all down

AAPL is killing me, closed at $609.84. I need blowout earnings Oct 25th, a $65 run up for my calls to make money. ....................................................................................... ACTC down again at 0.0733. With no news we go lower. ...................................................................................... Geron closed at $1.44 down we go. The BXT offer is better than nothing, but it's close to nothing. I'll vote for it.......................................................... ....................................................................................... Good luck in this rigged casino,

Great News for Stem Cell Believers

9:05AM Geron: BioTime (BTX) issues open letter to shareholders of Geron; proposes transaction between Biotime Acquisition and Geron (GERN) 1.42 : BioTime (BTX) issued a letter to the shareholders of Geron regarding Geron's stem cell assets. BTX proposes Geron shareholders could own up to 45% of a new publicly traded co that will own the Geron stem cell assets, $40 mln of BioTime stock, certain BioTime stem cell assets, and shares of certain BioTime stem cell subsidiaries. Geron shareholders would also receive BioTime stock-purchase warrants presently valued at ~$13 mln. Geron would retain its cancer therapy business, including Imetelstat and GRN1005, and its cash and short-term liquid investments and Geron shareholders would continue to own 100% of the Geron cancer therapy business through their ownership of Geron stock. Through the "Stem Cell Transaction", Geron would transfer its stem cell assets to BioTime Acq, in exchange for which you along with the other Geron shareholders would receive shares of BAC common stock representing ~21.4% of the outstanding BAC capital stock. BioTime would contribute to BAC the following assets in exchange for the balance of outstanding BAC capital stock: $40 mln in BioTime common shares; Warrants to purchase BioTime common shares; Rights to certain stem cell assets of BioTime, and shares of two BioTime subsidiaries engaged in the development of therapeutic products from stem cells. .............................................................................................................................................................................................................................................................. This is all Geron is going to get. I'm going to take it. I believe in the science. I hope BioTime restarts the Phase 1 trials on spinal injuries soon. Just hope I live long enough to see results. Geron is up over $1.51. BTX was up a penny................ Good luck in this rigged casino,

I Stopped Waiting AAPL up big

AAPL up big on the news of Ipod mini, closed at $649.79 up $15.03 on 19.5 million shares. The three month avg. volume 15.8 million shares. Need $30 more for my calls. . . . Geron is going no where fast closing again at $1.37 shares. The volume only 339,014 shares. No market interest, need good news or we go lower. . . . ACTC down again at 0.0725 on 3.7 million shares. The three month avg. volume is 5.7 million shares. Need more good news on the Phase 1/2 trials or we will go lower.. . . . Good luck in this rigged casino,

Still Waiting Geron, ACTC and AAPL

AAPL should start it's run up into earnings Oct 25th. Closed up $5.05 at $634.76. Need $40s to made money on my 3 calls...................................................... ......................................................................................................................................................................................................................................................................ACTC down just a little at 0.0735. Need news soon if not we go lower. ......................................................................................................................................................................................................................................................................Geron closed flat at $1.37, volume was only 264,971. Needs news soon or we go under $1.............................................................................................................................................................................Good luck in thiis rigged casino,

Waiting for news AAPL, ACTC and Geron

Waiting on AAPL's, iPod mini on Oct. 23rd and earnings Oct 25th. I need a $35 run up for my calls to make money.................................................. ...................................................................................... ...................................................................................... Geron we need good news on the last four phase two trials. If the news is poor Geron is done as a company................................................................. ,............................................................................................................................................................................. ACTC more good news on trials, a partner, listing on the big broad.................... .................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

AAPL up Geron and ACTC down

AAPL closed up $5.06 at $640.91 on 18.2 million shares. The three month avg. volume is 15.6 million Hoping for blow numbers on Oct 25th. ................................................................................................................................................................................................................................................................................................................................................................... ACTC was down a little at 0.074 on 4.4 million shares. The three month avg. volume is 6.2 million shares. Need more good news................................................ ..................................................................................................................................................................................................................................................................... Geron down 3 cents at $1.37 on 707,267 shares. The three month avg. volume is 1.6 month shares. Need good news on the last 4 remaining trials................................................................................. ..................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

GE Healthcare exercises option to Geron's cellular assay patents

08 October 2012 GE Healthcare exercises option to Geron’s cellular assay patents Agreement covers intellectual property relating to stem cell-based technologies for drug discovery and predictive toxicity screening CHALFONT ST. GILES, UK – 8 October 2012 – GE Healthcare, the healthcare business of GE (NYSE: GE), announced today that it has expanded its 2009 license agreement with Geron Corporation for the development of cellular assays and models derived from embryonic stem cells (ESC’s) for use in drug discovery and toxicity screening. Under the terms of the expanded license, GE Healthcare obtains exclusive global rights to Geron’s intellectual property and know-how for the development and sale of cellular assays derived from induced pluripotent stem cells (iPS). Financial terms were not disclosed. GE Healthcare is pioneering the development of human cell-based assays and models for use in drug discovery and predictive toxicity screening. As the worldwide pharmaceutical industry seeks to reduce the cost of drug development and to bring more effective, safer drugs to market, the availability of more biologically relevant and predictive cell models is becoming increasingly important. In 2010 the company launched CytivaTM cardiomyocytes (human heart cells), stem cell-based assays that are already helping pharmaceutical companies develop safer medicines by identifying - much earlier in the discovery process - drug candidates that show toxic effects. The company also plans to launch Cytiva hepatocytes (liver cells) for toxicity testing, and recently announced a collaboration with the Beijing Genomic Institute aimed at understanding the underlying genetic variation between ethnically diverse stem cell lines.................................................................................. ....................................................................................... Dr Amr Abid, General Manager, Cell Technologies, GE Healthcare Life Sciences said, “Expanding our agreement with Geron is a significant step forward and will help us realise our vision of bringing the benefits of stem cell derived assays and models to pharmaceutical and cell science research. In the immediate term it will allow us to accelerate the development of new technologies and products for our customers in drug discovery. Longer term, by taking a licence from GE Healthcare, the wider industry will also benefit from the ability to use key intellectual property without violating patent rights. This clarity and freedom to operate will, I believe, do much to advance the use of stem cell based assays in drug discovery................................... This is great news and Geron is down, but I think this news slowed Geron drop. Also Geron filed a 8-K, which is a sales agreement between Geron and MLV & Co. for up to $50 million in shares. Still Geron closed down 5 cents at $1.41 on only 542,024 shares. The three month avg. volume is 1.6 million shares. ........................... AAPL closed down $2.32 at $635.85 on almost 30 million shares. The three month avg. volume is 15.7 million shares. I think we're done going down till earnings on the 25th. ...................................................................................... ACTC closed under 8 cents on 11.5 million shares. The three month avg. volume is 6.2 million shares. I don't know why this company is down the news the day before was good. ......................................................................................... Good luck in this rigged casino,

ACTC great news on Stargardt's disease trials

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company’s three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of second and third additional patients with Stargardt’s macular dystrophy (SMD) in the second patient cohort of its U.S. trial for the condition. Additionally, the DSMB has authorized the Company to treat all three patients in the second cohort of its European trial for SMD. The UK Medicines and Healthcare products Regulatory Agency (MHRA) recently approved a protocol modification to the DSMB review, streamlining the process, allowing the company to treat the first patient in a new cohort if the DSMB has allowed this in the US study, and once clearance has been received in the US trial to treat the next two patients in the US cohort. This would also allow for treatment of the UK patients without an additional review by the DSMB. Moreover, according to the protocol for both trials, each patient in the second cohort will be injected with 100,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells, up from 50,000 in the first cohort. “This authorization to treat the next five patients in the second, higher-dosage cohort in both our clinical trials for SMD represents a significant step forward for our clinical programs,” commented Gary Rabin, chairman and CEO of ACT. “We are also encouraged with the MHRA’s approval of the DSMB’s streamlined review process. Clearly this has the potential to help accelerate the pace of our European trial.” ACT is conducting three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration, SMD and dry age-related macular degeneration (dry AMD). Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format, from 50,000 hESC-derived RPE cells in the first patient cohort to 200,000 in the last and final cohort. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry-AMD or SMD at 12 months, the study’s primary endpoint. “We are eagerly anticipating treating these final two patients in the second cohort of our U.S. trial for SMD, and all three patients in the second cohort of our E.U. trial,” commented Robert Lanza, M.D., ACT’s chief scientific officer. “We are encouraged by the preliminary data in the first patient in this second, higher-dosage cohort and look forward to gathering more data.” Further information about patient eligibility for ACT’s SMD studies in the U.S. and E.U. as well as its dry AMD study are available at www.clinicaltrials.gov, with the following Identifiers: NCT01345006 (U.S. SMD), NCT01469832 (E.U. SMD), and NCT01344993 (dry AMD).........................................................................AAPL down again, so I bought 4 more shares. I need a $50 run for my calls to be above water. ..................................................................................... Good luck in this rigged casino,

AAPL, ACTC and Geron all down again

Bad Day at Black Rock, great movie, somes up Friday. .................................. .............................................................................................................................................................................. AAPL down $14.21 to close at $652.59 on 21.2 million shares. The three month avg. volume is 15.3 million shares. I bought and sold one AAPL call. I have 3 AAPL calls, two at Feb 2013 $685 and one at Feb 2013 $690. Need about $20+ run to made some money. .....................................................................................................................................................................................................................................................................ACTC closed down a little at 0.07 on 8 million shares. The three month avg. is 6 million shares. Need good news or we continue down..................................... ..................................................................................................................................................................................................................................................................... Geron down, down, down we go. Closed at $1.41. I'm thinking the big boys are running Geron down, then will run it back up before Dec 5th, when Geron tells us how the Phrase two trails are going. Just like they did before Geron give us the bad news on two of the Phase two trials. So if this happens will sell some and write a few covered calls.................................................................................................................................................................................................................................................................Good luck in this rigged casino,

ACTC, AAPL and GERON all down

Not good, all three stocks down on a up day............................................ .............................................................................................................................................................................. AAPL down $4.65 to close at $666.80 on 13.1 million shares. Bought a $685 Feb 2013 call and then sold it, made a little money. Then bought it back again at the end of the trading day. AAPL still is the best company out there............................. .............................................................................................................................................................................. ACTC down a little again at 0.0725 on 9.3 million shares. The 10 day avg. volume is 6.2 million shares. With no news we go lower........................................... .............................................................................................................................................................................. Geron closed down 3 cents at $1.59 on only 503,531 shares. The 10 day avg. is 1.2 million shares. With no news we go lower............................................... .............................................................................................................................................................................. Good luck in this rigged casino,

Geron and ACTC going nowhere

Geron down again to $1.62 on only 570,000 shares. The three month avg. volume is 1.6 million shares. No news, no interest............................................... .............................................................................................................................................................................. ACTC down again to 0.0727 on 5.5 million shares. The three month avg. volume is 6 million shares. Need news or we go lower.......................................... ..................................................................................................................................................................................................................................................................... AAPL up $10.14 to close at $671.45 on 15.1 million shares. The three month avg volume is 15.1 million shares. I bought two $690 call for Feb 2013, on Monday. Sold one today made $208 and will sell the 2nd this week I hope, need $7 more dollars. Earnings Oct 15th ................ ........................................................... ...................................................................................................................................................................... Good luck in this rigged casino,